What topics should be included in the Effects in Humans: Introduction with respect to pharmacokinetics data?

• A. Only safety data
• B. Pharmacokinetics, Bioavailability, Population subgroups, Interactions, and Other PK data
• C. Labeling requirements
• D. Patent status

Answer: (B)

The main idea is that the Effects in Humans section for pharmacokinetics data should present a full picture of how the drug behaves in humans, not just safety signals. It belongs with the pharmacokinetic profile itself and the factors that shape exposure. So the discussion should include the basic PK information—absorption, distribution, metabolism, and excretion—as well as bioavailability and the extent and rate of absorption. It should also cover how the drug’s exposure can be influenced by real-world factors like food effects and different routes of administration. Important subtopics include how various population subgroups (age, sex, race, genetic factors, hepatic or renal impairment, and other comorbid conditions) may alter PK, and how potential drug–drug interactions with inhibitors or inducers or transporter modulators can change exposure. Any other PK data that informs how the drug behaves in humans should be included as well. Choice topics focused solely on labeling requirements or patent status relate to regulatory or intellectual property aspects, not the pharmacokinetic profile, and thus do not fit the scope of this section.